Core Viewpoint - ATHA Energy Corp. has announced a private placement of up to 24,510,000 flow-through shares at a price of $1.02 per share, aiming for gross proceeds of up to $25,000,200, with the potential to increase to C$28,750,230 if an additional option is fully exercised [1][2]. Group 1: Offering Details - The offering will be conducted by Canaccord Genuity Corp. and CIBC World Markets as co-lead agents and joint bookrunners [1]. - The expected closing date for the offering is around February 5, 2026, subject to regulatory approvals [4]. - The flow-through shares will be offered to purchasers in Canada and other qualifying jurisdictions, exempt from certain conditions under National Instrument 45-106 [5]. Group 2: Use of Proceeds - The gross proceeds from the sale of the flow-through shares will be used to incur eligible "Canadian exploration expenses" related to the Company's projects in Canada, specifically for flow-through critical mineral mining expenditures [3]. - The Company plans to renounce all qualifying expenditures to subscribers of the flow-through shares by December 31, 2026 [3]. Group 3: Company Overview - ATHA Energy Corp. is focused on the acquisition, exploration, and development of uranium assets, with a portfolio that includes three 100%-owned uranium projects and a large exploration land package exceeding 7 million acres [8]. - The Company also holds a 10% carried interest in key exploration projects in the Athabasca Basin operated by NexGen Energy Ltd. and IsoEnergy Ltd [9].

Core Points - Quantum BioPharma Ltd. has announced a public whistleblower policy offering rewards up to USD $7 million for information leading to a trial victory or settlement in its ongoing lawsuit against major financial institutions for stock manipulation [1][3][9] - The lawsuit seeks over USD $700 million in damages due to alleged illegal tactics, including "spoofing," which artificially depressed the company's stock price from approximately USD $460 in early 2020 to less than USD $10 by late 2024 [10][9] - The company emphasizes its commitment to restoring market integrity and holding alleged perpetrators accountable through this initiative [5][12] Whistleblower Policy - The cash reward will be granted if the information significantly contributes to a final judgment or binding settlement [3][4] - Eligible information includes evidence of illegal trading practices, such as spoofing and spreading false information [3][4] - The program does not interfere with existing SEC whistleblower programs, allowing individuals to report directly to the SEC while also participating in Quantum's initiative [6][7] Legal Context - The lawsuit is characterized as one of the largest spoofing cases in decades, with substantial evidence gathered by experienced law firms [10][12] - The company is actively seeking additional evidence and information from individuals who may have knowledge of the alleged manipulation [13][11] - Legal representation is provided on a contingency basis, meaning the company incurs no upfront legal costs [10] Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [14] - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., with a royalty agreement that could yield significant future revenues [14] - The company is committed to involving its shareholder community in addressing the impacts of stock manipulation [13]

Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities in a market manipulation lawsuit, alleging damages exceeding $700 million USD due to "spoofing" techniques that artificially depressed its stock price [1][2][4]. Legal Proceedings - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants engaged in market manipulation that violated the Securities Exchange Act of 1934 [2]. - Quantum BioPharma's amended complaint was filed on May 31, 2025, in response to the defendants' memorandum of law filed on June 16, 2025 [2][3]. Financial Implications - Quantum BioPharma is seeking over $700 million USD in damages due to the alleged market manipulation [2]. - The company's stock was trading over $460 USD per share in January 2020, with a market capitalization approaching $1 billion USD [5]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted an extensive investigation and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Background - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement that could yield up to $250 million [10].

Core Viewpoint - Quantum BioPharma Ltd. has filed a memorandum of law opposing a joint motion to dismiss by CIBC World Markets and RBC Dominion Securities, alleging market manipulation that harmed the company's stock price and seeking over $700 million in damages [1][2]. Legal Proceedings - The company filed an amended complaint on May 31, 2025, alleging that the defendants engaged in market manipulation schemes violating the Securities Exchange Act of 1934 [2]. - The lawsuit claims that from January 1, 2020, to August 15, 2024, the defendants used "spoofing" techniques to manipulate Quantum BioPharma's share price [2][4]. - The company has made all relevant legal documents available on its website for public access [3]. Financial Impact - Quantum BioPharma's stock was trading over $460 per share in January 2020, with a market capitalization nearing $1 billion [5]. - The company is seeking damages exceeding $700 million due to the alleged manipulation, which it claims has significantly harmed both the company and its investors [2][4]. Legal Representation - The law firms Christian Attar and Freedman Normand Friedland LLP are representing Quantum BioPharma on a contingency basis, meaning the company will not face immediate financial pressure for legal costs [4]. - These firms have conducted extensive investigations and believe there is sufficient evidence to support the claims of market manipulation [4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [9]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [10]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., with a royalty agreement that could yield significant future revenue [10].

Core Viewpoint - Quantum BioPharma Ltd. has made a strategic investment by purchasing 2,000 shares of GameStop Corp. to enhance shareholder value and combat market corruption [1][4]. Group 1: Strategic Investments - The acquisition of GameStop shares is part of Quantum BioPharma's strategy to deploy capital towards undervalued assets with strong fundamentals [4]. - Kevin Malone, Board Advisor, highlighted the value in GameStop, noting that the company holds 90% cash and marketable securities on its balance sheet [5]. Group 2: Advocacy Against Market Manipulation - Quantum BioPharma has appointed advocates like Kevin Malone and Terry Lynch to combat market corruption, particularly against naked short selling and stock manipulation [2]. - The company has filed an amended complaint seeking damages exceeding $700 million against CIBC World Markets and RBC Dominion Securities for alleged stock price manipulation through spoofing techniques [3]. Group 3: Shareholder Value Initiatives - The company is advancing its Multiple Sclerosis Patented New Chemical Entity asset and intends to declare a special dividend tied to potential litigation settlements [4]. - Quantum BioPharma has completed a debt settlement by issuing Class B shares, further demonstrating its commitment to prudent financial management [6]. Group 4: Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation in multiple sclerosis [8]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement for sales from its product unbuzzd™ [8].

Core Viewpoint - Quantum BioPharma Ltd. intends to declare a special dividend consisting of Contingent Value Rights (CVRs) to holders of its Class B Subordinate Voting Shares, reflecting the company's commitment to its shareholders [1][3]. Group 1: Special Dividend and CVRs - Each CVR will entitle holders to receive a pro rata portion of a minimum of 10% and a maximum of 50% of the net proceeds from the company's legal action against certain banks, seeking damages exceeding USD 700 million for alleged stock price manipulation [2][8]. - The exact payout percentage for the CVRs will be approved by the Board at a later date [2][3]. - The record date for the proposed special dividend has not yet been established, and further updates will be provided [3]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [4]. - The company’s lead compound, Lucid-MS, aims to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [4][8]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach USD 250 million, after which the royalty will drop to 3% [4]. Group 3: Legal and Regulatory Considerations - The issuance of the CVRs is subject to necessary approvals, regulatory requirements, and finalization of tax, legal, and operational matters [3][8]. - There is no assurance that any proceeds from the litigation will be received or that the CVRs will result in any payment to holders [3][7].

Core Viewpoint - Quantum BioPharma Ltd. has filed an amended complaint alleging market manipulation by several banks, seeking damages exceeding $700 million USD due to the alleged manipulation of its stock price through "spoofing" techniques from January 2020 to August 2024 [1][2][3]. Group 1: Legal Proceedings - The amended complaint was filed on May 1, 2025, in response to a Motion to Dismiss from the banks [1]. - The lawsuit claims that CIBC World Markets and RBC Dominion Securities, among others, violated the Securities Exchange Act of 1934 [1][2]. - The law firms Christian Attar and Freedman Normand Friedland LLP are representing the company on a contingency basis, alleviating financial pressure for legal costs [2]. Group 2: Allegations of Market Manipulation - The complaint alleges that the defendants engaged in "spoofing" techniques that artificially depressed Quantum BioPharma's stock price [2]. - The company asserts that the stock was trading over $460 USD per share in January 2020, with a market capitalization nearing $1 billion USD [3]. - Quantum BioPharma believes that additional banks and brokers may also be involved in the alleged manipulation but will not disclose their names until more evidence is gathered [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [7]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [8]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which includes a royalty agreement on sales from its product unbuzzd™ [8].